Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243290 · ClinicalTrials.gov registry record · NA
Nicotinamide Riboside Clinical Trial for GWI
A NA study of Gulf War Illness, sponsored by Roskamp Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT05243290: Recruiting NA study of Gulf War Illness, sponsored by Roskamp Institute.
NCT05243290 is a NA study of Gulf War Illness that is actively recruiting participants, run by Roskamp Institute. The registered enrollment target is 52 participants, below the 126-participant average among 14 other Gulf War Illness trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05243290, a NA study of Gulf War Illness, is actively recruiting participants, sponsored by Roskamp Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
Primary Outcome
The primary objective is to determine if NR can increase plasma NAD+ levels in GWI veterans.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Nicotinamide Riboside
Study Locations (2)
Florida
- Nova Southeastern University - Fort Lauderdale
- The Roskamp Institute - Sarasota
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT05243290 shows while recruiting
NCT05243290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 126-participant average among 14 other Gulf War Illness trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Gulf War Illness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05243290 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05243290 about?
NCT05243290 is a clinical study titled "Nicotinamide Riboside Clinical Trial for GWI". In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
What is the current status of trial NCT05243290?
This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2022-04-13. Estimated completion is 2025-12-31.
What conditions does trial NCT05243290 study?
This clinical trial studies the following conditions: Gulf War Illness.
What interventions are being tested in trial NCT05243290?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nicotinamide Riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05243290?
This trial is sponsored by Roskamp Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05243290 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gulf War Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05243290's enrollment target sits among peer trials
52 12th of 14 higher than 2 of 14 other Gulf War Illness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gulf War Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Gulf War Illness
RECRUITING · NA
-
Pilot Test of Apnea and Insomnia Relief for Veterans With Gulf War Illness
ACTIVE NOT RECRUITING · NA
-
Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI
ACTIVE NOT RECRUITING · NA
-
Collaborative Specialty Care for Gulf War Illness
ACTIVE NOT RECRUITING · NA
-
Confirmation of Diet as a Treatment for Gulf War Illness
RECRUITING · Phase 3
-
NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI